Cases 11 - 20 of 106
ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited et al
as 1:2022cv01387
Plaintiff:
ACADIA Pharmaceuticals Inc.
Defendant:
Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Alcon Inc. et al v. Aurobindo Pharma Ltd. et al
as 1:2022cv01391
Plaintiff:
Alcon Inc. and Alcon Laboratories, Inc.
Defendant:
Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Array BioPharma, Inc. v. Eugia Pharma Specialities Limited et al
as 1:2022cv01236
Plaintiff:
Array BioPharma, Inc.
Defendant:
Eugia Pharma Specialities Limited and Aurobindo Pharma USA, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Bial - Portela & CA S.A. et al v. Aurobindo Pharma Ltd. et al
as 1:2022cv01270
Plaintiff:
Bial - Portela & CA S.A., Bial - Holding, S.A. and Sunovion Pharmaceuticals Inc.
Defendant:
Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Aragon Pharmaceuticals, Inc. et al v. Eugia Pharma Specialities Limited et al
as 1:2022cv00688
Defendant:
Eugia Pharma Specialities Limited, Eugia Pharma Specialties Limited, Aurobindo Pharma USA, Inc. and others
Plaintiff:
Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., The Regents of the University of California and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Merck Sharp & Dohme Corp. et al v. Aurobindo Pharma Limited et al
as 1:2022cv00377
Plaintiff:
MSD International Business GmbH, MSD International GmbH, Pfizer Inc. and others
Defendant:
Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al
as 1:2018cv01043
Defendant:
Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc. and others
Counter Claimant:
Biocon Limited, HEC Pharm Group, HEC Pharm Co., Ltd. and others
Counter Defendant:
Novartis Pharmaceuticals Corporation
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Amgen Inc. et al v. Aurobindo Pharma Limited et al
as 1:2022cv00227
Plaintiff:
Amgen Inc. and KAI Pharmaceuticals, Inc.
Defendant:
Aurobindo Pharma Limited, Aurobindo Pharma USA Inc., Eugia Pharma Specialties Limited and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Entresto (Sacubitril/Valsartan) Patent Litigation
as 1:2020md02930
Counter Claimant:
Biocon Pharma Limited, Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd. and others
Not Classified By Court:
Hetero USA Inc.,, Torrent Pharma Inc., Zydus Pharmaceuticals (USA) Inc. and others
In Re:
Entresto (Sacubitril/Valsartan) Patent Litigation
Counter Defendant:
Novartis Pharmaceuticals Corporation
Defendant:
Noratech Labs, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Novo Nordisk Inc. et al v. Aurobindo Pharma USA, Inc. et al
as 1:2022cv00295
Plaintiff:
Novo Nordisk Inc. and Novo Nordisk A/S
Defendant:
Aurobindo Pharma USA, Inc., Aurobindo Pharma Ltd. and Eugia Pharma Specialties Ltd.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
